

# Forschungsprojekte 2018

## Projets de recherche 2018

Unterstützt von: / Soutenus par:

**krebsforschung schweiz**  
 recherche suisse contre le cancer  
 ricerca svizzera contro il cancro  
 swiss cancer research

<b>Grundlagenforschung / Recherche fondamentale</b>			
<b><u>Gesuchsteller/In</u></b>	<b><u>Projektnummer</u> <u>Projekttitel</u></b>	<b><u>Dauer</u> <u>(Monate)</u></b>	<b><u>Betrag</u> <u>(CHF)</u></b>
<b><u>Candidat/e</u></b>	<b><u>Numéro du projet</u> <u>Titre du projet</u></b>	<b><u>Durée</u> <u>(mois)</u></b>	<b><u>Montant</u> <u>(CHF)</u></b>
<b>Altmeyer Matthias</b> , Prof. Dr. Department of Molecular Mechanisms of Disease University of Zurich (UZH) 8057 Zurich	KFS 4406-02-2018 PARP inhibitor sensitization by deregulated PARP1 turnover in cancer	36	361 300.–
<b>Arber Caroline</b> , Prof. Dr. med. Oncology Centre hospitalier universitaire vaudois (CHUV) 1066 Epalinges	KFS 4542-08-2018 Engineering T-cells to target multiple myeloma	36	375 000.–
<b>Becher Burkhard</b> , Prof. Dr. Institute of Experimental Immunology University of Zurich (UZH) 8057 Zurich	KFS 4431-02-2018 Harnessing innate lymphoid cell surveillance of cancer metastasis	36	334 900.–
<b>Bentires-Alj Mohamed</b> , Prof. Dr. Departement Biomedizin Universitätsspital Basel 4031 Basel	KFS 4414-02-2018 Assessing the effects of protein tyrosine phosphatase SHP2 on immune cells in models of metastatic breast cancer	36	375 000.–
<b>Chijioke Obinna</b> , Dr. Institute of Experimental Immunology University of Zurich (UZH) 8057 Zurich	KFS 4371-02-2018 NK cells driving CARs	36	372 000.–
<b>Constam Daniel</b> , Prof. Dr Faculté de sciences de la vie SV EPF de Lausanne (EPFL) 1015 Lausanne	KFS 4454-02-2018 Melanoma immune surveillance by activin-A and its role in anti-PD-1 immune checkpoint therapy	48	371 050.–

<b>Cosset Erika, Dr.</b> Department of Internal Medicine Specialities Université de Genève (UNIGE) 1206 Genève	KFS 4554-08-2018 A new role for Galectin-3 in glioblastoma aggressiveness	36	367 500.–
<b>Geiger Roger, Dr.</b> Immune Regulation Institute for Research in Biomedicine (IRB) 6500 Bellinzona	KFS 4593-08-2018 The role of fatty acid metabolism in the anti-tumour T-cell response	36	363 750.–
<b>Hajnal Alex, Prof. Dr.</b> IMLS Institute University of Zurich (UZH) 8057 Zurich	KFS 4377-02-2018 Studying developmental cell invasion in the nematode <i>C. elegans</i> to understand tumour cell metastasis	36	324 800.–
<b>Hegi Monika, Prof. Dr</b> Department of Clinical Neurosciences Centre hospitalier universitaire vaudois (CHUV) 1066 Epalinges	KFS 4461-02-2018 Targeting the epigenome of glioblastoma	36	272 750.–
<b>Held Werner, Prof. Dr</b> Department of Oncology University of Lausanne (UNIL) 1066 Epalinges	KFS 4407-02-2018 Exploiting memory-like CD8 T-cells to improve tumour immunotherapy	36	361 750.–
<b>Hutter Gregor,</b> Dr. med., Dr. sc. nat. Neurochirurgische Klinik Universitätsspital Basel 4031 Basel	KFS 4386-02-2018 The role of microglia and its modulation in glioblastoma	48	323 050.–
<b>Jandus Camilla, Dr</b> Department of Fundamental Oncology University of Lausanne (UNIL) 1066 Epalinges	KFS 4402-02-2018 Innate lymphoid cells (ILCs) as novel, targetable immune regulators in bladder cancer patients	36	374 950.–
<b>Johnson Rory, Prof. Dr</b> Department of Clinical Research University of Bern 3008 Bern	KFS 4534-08-2018 Multi-phenotype genome-engineering screens for long intergenic non-coding RNAs driving non-small cell lung cancer	36	359 350.–
<b>Jungraithmayr Wolfgang,</b> Prof. Dr. Klinik für Thoraxchirurgie UniversitätsSpital Zürich (USZ) 8091 Zürich	KFS 4144-02-2017 A new therapeutic concept against lung cancer by inhibition of CD26/DPP4	24	251 600.–
<b>Katanaev Vladimir, Prof. Dr</b> Pharmacology and Toxicology University of Lausanne (UNIL) 1011 Lausanne	KFS 4379-02-2018 Cancer as 'information disease': application of the principles of information theory to signal transduction in cancer cells	36	360 350.–

<b>Levesque Mitchell</b> , Prof. Dr. Dermatologische Klinik UniversitätsSpital Zürich (USZ) 8091 Zürich	KFS 4459-02-2018 Multi-omic, single-cell profiling of melanoma for predictive biomarker identification in check-point blockade	24	250 000.–
<b>Martinou Jean-Claude</b> , Prof. Dr Département de biologie cellulaire (BICEL) Université de Genève (UNIGE) 1211 Genève	KFS 4434-02-2018 Genetic and pharmacological inhibition of the mitochondrial pyruvate carrier: effects on tumour growth and metastasis	18	160 150.–
<b>Nevado Cristina</b> , Prof. Dr. Department of Chemistry University of Zurich 8057 Zurich	KFS 4585-08-2018 Optimization of bromodomain blockers for the treatment of castration-resistant prostate cancer	24	249 300.–
<b>Penengo Lorenza</b> , Prof. Dr Institute of Molecular Cancer Research University of Zurich 8057 Zurich	KFS 4577-08-2018 High DNA replication speed promoted by the interferon stimulated gene 15 as a novel strategy for chemosensitization	36	375 000.–
<b>Petrasch Ulf</b> , PD Dr. med. Institut für Experimentelle Immunologie Universität Zürich (UZH) 8057 Zürich	KFS 4231-08-2017 Optimizing CAR-T cells with PD-1/PD-L1 blockade for the treatment of malignant pleural mesothelioma	6	47 775.–
<b>Roth Patrick</b> , PD Dr. med. Department of Neurology University Hospital Zurich 8091 Zurich	KFS 4544-08-2018 Integrins as targets for advanced chimeric antigen receptor (CAR) T cell treatment of glioblastoma	36	352 300.–
<b>Rüegg Curzio</b> , Prof. Dr med. Department of Medicine University of Fribourg 1700 Fribourg	KFS 4400-02-2018 Mechanisms and therapeutic targets of breast cancer metastatic colonization	36	357 800.–
<b>Rufer Nathalie</b> , Dr Department of Oncology University of Lausanne (UNIL) 1066 Epalinges	KFS 4368-02-2018 Impact of TCR-ligand avidity on cell function, memory/survival, persistence and migration to tumour lesions of anti-cancer CD8 T-cell clonotypes	36	370 100.–
<b>Santoro Raffaella</b> , PD Dr Molecular Mechanisms of Disease University of Zurich (UZH) 8057 Zurich	KFS 4527-08-2018 Towards personalized medicine of prostate cancer: modelling of prostate cancer heterogeneity through organoid technology	30	306 950.–
<b>Skoda Radek C.</b> , Prof. Dr med. Department of Biomedicine University Hospital Basel 4031 Basel	KFS 4462-02-2018 Targeting metabolic alterations and extra-medullary haematopoiesis to treat myeloproliferative neoplasms	36	374 250.–

<b>Sommer Lukas</b> , Prof. Dr. Anatomisches Institut Universität Zürich (UZH) 8057 Zürich	KFS 4570-08-2018 Mechanisms governing melanoma initiation, progression, and therapy resistance	36	375 000.–
<b>Stockmann Christian</b> , Dr med. Institute of Anatomy University of Zurich (UZH) 8051 Zurich	KFS 4397-02-2018 Tuning of oxygen sensing in adoptive NK cell transfer for cancer therapy	36	366 000.–
<b>Sturla Shana</b> , Prof. Dr Health Sciences and Technology ETH Zurich 8092 Zurich	KFS 4443-02-2018 A molecular basis for stratifying patients with acute lymphoblastic leukaemia for personalized pro-drug therapy	48	368 300.–
<b>Tang Li</b> , Prof. Dr Institute of Bioengineering, Institute of Materials Science & Engineering Ecole Polytechnique Fédérale de Lausanne (EPFL) 1015 Lausanne	KFS 4600-08-2018 Delivery of cancer neoantigen vaccine with a carrier-free nanogel for personalized immunotherapy	48	313 950.–
<b>Vozenin Marie-Catherine</b> , Dr Service de Radio-Oncologie Centre hospitalier universitaire vaudois (CHUV) 1011 Lausanne	KFS 4438-02-2018 Phase III clinical trial: therapeutic efficacy of FLASH-RT in domestic cats with superficial carcinoma of the nasal planum	48	186 750.–
<b>Werner Sabine</b> , Prof. Dr Biology ETH Zurich 8093 Zurich	KFS 4510-08-2018 Roles and mechanisms of action of the growth and differentiation factor activin in skin carcinogenesis	36	366 900.–
<b>Zhang Ye</b> , Dr Centre for Proton Therapy Paul Scherrer Institut (PSI) 5232 Villigen-PSI	KFS 4517-08-2018 Towards online MRI guided scanned proton therapy	48	321 100.–

<b>Klinische Forschung / Recherche clinique</b>			
<b>Gesuchsteller/In</b>	<b>Projektnummer Projekttitel</b>	<b>Dauer (Monate)</b>	<b>Betrag (CHF)</b>
<b>Candidat/e</b>	<b>Numéro du projet Titre du projet</b>	<b>Durée (mois)</b>	<b>Montant (CHF)</b>
<b>Blum Sabine</b> , Dr med. Oncologie, Service d'hématologie Centre hospitalier universitaire vaudois (CHUV) 1011 Lausanne	KFS 4412-02-2018 A randomized phase II multicentre study to assess the tolerability and efficacy of the addition of midostaurin to 10-day decitabine in UNFIT (i.e. HCT-CI $\geq$ 3) adult AML and high risk myelodysplasia (MDS) (IPSS-R > 4.5) patients	19	191 900.–
<b>Bornhauser Beat</b> , Dr Oncology University Children's Hospital Zurich 8008 Zurich	KFS 4384-02-2018 RIPping off novel cell death pathways to eradicate drug resistant leukaemia	36	375 000.–
<b>Bourquin Carole</b> , Prof. Dr Section of Pharmaceutical Sciences University of Geneva 1211 Genève	KFS 4535-08-2018 Impact of obesity on anti-tumour response to immunotherapy	36	368 850.–
<b>Ghielmini Michele</b> , Prof. Dr Ospedale Regionale Bellinzona e Valli (ORBV) Istituto oncologico della Svizzera italiana (IOSI) 6500 Bellinzona	KFS 4395-02-2018 Multilayer model for personalized risk stratification of follicular lymphoma patients	36	330 800.–
<b>Heinzelmann-Schwarz Viola</b> , Prof. Dr Gynecological Oncology University Hospital Basel 4031 Basel	KFS 4586-08-2018 Maintenance therapy with aromatase inhibitor in epithelial ovarian cancer: a phase III randomized double-blind placebo-controlled trial (MATAO trial)	48	375 000.–
<b>Hrbacek Jan</b> , Dr Center for Proton Therapy Paul Scherrer Institut (PSI) 5232 Villigen	KFS 4447-02-2018 Clip-free ocular proton therapy	24	247 700.–
<b>Moeckli Raphaël</b> , Dr Institut de Radiophysique Centre hospitalier universitaire vaudois (CHUV) 1007 Lausanne	KFS 4399-02-2018 Multi-criteria decision making in radiotherapy: robustness and clinical regions of interest of pareto fronts	48	232 950.–
<b>Ng Kiu Yan Charlotte</b> , Dr Biomedicine University of Basel 4031 Basel	KFS 4543-08-2018 Single-cell dissection of the cellular ecosystem in hepatocellular carcinoma	48	250 350.–

<b>Peters Solange</b> , Prof. Dr med. Centre Pluridisciplinaire d'Oncologie Centre hospitalier universitaire vaudois (CHUV) 1011 Lausanne	KFS 4555-08-2018 Characterization of sugar usage by pro- tumour neutrophils in lung cancer	36	340 350.–
<b>Pless Miklos</b> , Prof. Dr. Medizinische Onkologie Kantonsspital Winterthur 8401 Winterthur	KFS 4381-02-2018 Comparison of PD-L1 expression before and after neoadjuvant chemoradiation or chemotherapy in stage III non-small cell lung cancer. A retrospective analysis	12	31 650.–
<b>Radtke Freddy</b> , Prof. Dr SV 2534 EPF de Lausanne 1015 Lausanne	KFS 4513-08-2018 Neutrophil mediated immune-suppression in colorectal cancer	36	365 200.–
<b>Riether Carsten</b> , PD. Dr sc. nat. Department of BioMedical Research University of Bern 3008 Bern	KFS 4389-02-2018 IL-21/IL-21R signalling in leukaemia stem cells	48	325 000.–
<b>Romero Pedro</b> , Prof. Dr med. Department of Oncology University of Lausanne (UNIL) 1066 Epalinges	KFS 4404-02-2018 Translating insights on murine T-cell metabolic intervention to the clinical theater	36	361 750.–
<b>Soysal Savas Deniz</b> , PD Dr med. Surgery University Hospital Basel 4031 Basel	KFS 4375-02-2018 Stromal gene expression signatures: a predictive marker for associated malignancy in breast biopsies of uncertain malignant potential to reduce open surgical excisions	36	318 400.–
<b>Tausch Christoph</b> , PD Dr. med. Surgery Brust-Zentrum Zürich 8008 Zürich	KFS 4426-02-2018 VISION I: vacuum assisted biopsy immediately before surgery as an intra- or peri-operative comparison for patients who underwent neoadjuvant chemotherapy for breast cancer	48	370 550.–
<b>Unkelbach Jan</b> , Prof. Dr. Klinik für Radio-Onkologie UniversitätsSpital Zürich (USZ) 8091 Zürich	KFS 4528-08-2018 Combined proton-photon radiotherapy	36	336 400.–
<b>Velin Dominique</b> , Dr Service de gastro-entérologie et d'hépatologie Centre hospitalier universitaire vaudois (CHUV) 1066 Epalinges	KFS 4452-02-2018 Role of helicobacter pylori infection in the response to cancer immunotherapies	36	300 050.–

<b>Zander Thilo</b> , Dr. med. Innere Medizin/Onkologie Luzerner Kantonsspital 6000 Luzern	KFS 4564-08-2018 SAKK 39/16 – OptiPOM: alternate day dosing of pomalidomide in patients with refractory multiple myeloma. A multicentre, single arm phase II trial	36	351 300.–
<b>Zenz Thorsten</b> , Prof. Dr. Zentrum für Hämatologie und Onkologie UniversitätsSpital Zürich (USZ) 8091 Zürich	KFS 4439-02-2018 The landscape of drug combination effects in leukaemia & lymphoma	36	245 450.–
<b>Zlobec Inti</b> , Prof. Dr. phil. nat. Institut für Pathologie Universität Bern 3008 Bern	KFS 4427-02-2018 Refining risk-stratification for colorectal cancer patients: convolutional neural network analysis of histological images to predict outcome and molecular subtyping	36	361 250.–

<b>Psychosoziale Forschung / Recherche psychosociale</b>			
<b>Gesuchsteller/In</b>	<b>Projektnummer Projekttitle</b>	<b>Dauer (Monate)</b>	<b>Betrag (CHF)</b>
<b>Candidat/e</b>	<b>Numéro du projet Titre du projet</b>	<b>Durée (mois)</b>	<b>Montant (CHF)</b>
<b>Barth Jürgen</b> , PD Dr. phil. Institute for Complementary and Integrative Medicine University Hospital Zurich 8091 Zurich	KFS 4556-08-2018 Effectiveness of a mindfulness and relaxation self-care app for cancer patients: a randomized controlled multicentre study	36	359 400.–
<b>Bourquin Sachse Céline</b> , Dr Service de Psychiatrie de Liaison Centre hospitalier universitaire vaudois (CHUV) 1011 Lausanne	KFS 4401-02-2018 Towards “second generation” communication trainings in cancer care: in search of meaningful outcome measures	18	152 350.–
<b>Guttormsen Sissel</b> , Prof. Dr Medical Faculty Institute of Medical Education University of Bern 3012 Bern	KFS 4522-08-2018 Communication with cancer patients and their families about approaching death: scaffolding conceptual and practical learning for health professionals	36	374 950.–
<b>Jenewein Josef</b> , Prof. Dr. Klinik für Psychiatrie und Psychotherapie UniversitätsSpital Zürich (USZ) 8091 Zürich	KFS 4413-02-2018 Dignity therapy+: a brief psychological and existential intervention for dying patients and their families	24	147 500.–
<b>Pautex Sophie</b> , Prof. Dr med. Unité de soins palliatifs communautaires Hôpitaux universitaires de Genève (HUG) 1224 Chêne-Bougeries	KFS 4390-02-2018 "Revie ⊕" Impact of a resource-based life review intervention on advanced cancer patients in an oncological outpatient centre: a waitlist randomized controlled trial	36	134 700.–

**Epidemiologische Forschung / Recherche épidémiologie**

<b>Gesuchsteller/In</b>	<b>Projektnummer Projekttitel</b>	<b>Dauer (Monate)</b>	<b>Betrag (CHF)</b>
<b>Candidat/e</b>	<b>Numéro du projet Titre du projet</b>	<b>Durée (mois)</b>	<b>Montant (CHF)</b>
<b>Locatelli Isabella, Dr</b> DUMSC, IUMSP Central University Hospital of Vaud (CHUV) 1010 Lausanne	KFS 4385-02-2018 Predicting cancer incidence and annual number of new cancer cases in Switzerland up to 2025	36	184 400.–



# Stipendien 2018

## Bourses 2018

---

Unterstützt von: / Soutenus par:

**krebsforschung schweiz**  
recherche suisse contre le cancer  
ricerca svizzera contro il cancro  
**swiss cancer research**

<b>Gesuchsteller/In</b>	<b>Projektnummer Projekttitel</b>	<b>Dauer (Monate )</b>	<b>Betrag (CHF)</b>
<b>Candidat/e</b>	<b>Numéro du projet Titre du projet</b>	<b>Durée (mois)</b>	<b>Montant (CHF)</b>
<b>Finazzi Tobias, Dr</b> Radiation Oncology University Hospital Basel 4031 Basel	BIL KFS 4380-02-2018 Evaluating the benefit of stereotactic MRI-guided adaptive radiotherapy for early-stage non-small cell lung cancer  Destination: Department of Radiation Oncology, VU University Medical Center, Amsterdam (NL)	18	19 000.–
<b>Kienzler Jenny Christine,</b> Dr. med. Neurosurgery Kantonsspital Aarau AG 8048 Zürich	BIL KFS 4563-08-2018 Improvement in treatment of brain metastases - timing of radiosurgery in relation to surgery and immunotherapy for best local control - comparison of endogenous immune response and genetic signature of the tumour microenvironment between primary tumours and brain metastases  Destination: David Geffen School of Medicine, Department of Neuro-surgery, Brain Tumor Center, University of Los Angeles (USA)	24	105 000.–
<b>Meier Marie-Anne</b> Department of Biomedicine University Hospital Basel 4059 Basel	MD-PhD 4500-06-2018 SAMW MD-PhD Stipendium / Molecular signature of extracellular vesicles in liver cancer: effects of epithelial-mesenchymal transition and response to sorafenib  Destination: Department of Gastroenterology and Hepatology, University Hospital Basel	36	188 250.–

<p><b>Rohner Eliane</b>, Dr Institute of Social and Preventive Medicine (ISPM) University of Bern 3012 Bern</p>	<p>BIL KFS 4423-02-2018 Urine-based HPV testing: evaluation of a novel cervical cancer screening method</p> <p>Destination: UNC Gillings School of Global Public Health, University of North Carolina at Chapel Hill (USA)</p>	<p>24</p>	<p>99 600.–</p>
<p><b>Schmid Sabine</b>, Dr med. Medical Oncology Kantonsspital St. Gallen (KSSG) 9007 St. Gallen</p>	<p>BIL KFS 4393-02-2018 Lung cancer early detection and classification using methylome analysis of plasma cell-free DNA</p> <p>Destination: Department of Medical Oncology and Hematology, UHN Princess Margaret Cancer Center, Toronto (CA)</p>	<p>24</p>	<p>154 000.–</p>